论文部分内容阅读
目的评价恶性血液病患者并发革兰阳性(G+)球菌感染时,利奈唑胺治疗的疗效和安全性。方法收集2009年8月至2010年2月16例恶性血液病患者,平均年龄(45.6±5.8)岁。在明确诊断并发G+球菌感染或万古霉素治疗无效时,给予利奈唑胺注射液治疗,同时观察用药前后疗效和不良反应。结果在最初的经验性治疗疗效不佳后,患者采用利奈唑胺治疗,痊愈15例(93.7%),无效1例(6.3%)。细菌清除率93.7%。临床不良反应2例(12.5%),主要为不同程度丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)升高,无血常规检测异常。经保肝治疗后肝功均能恢复正常。结论利奈唑胺是治疗恶性血液病患者并发G+球菌感染的良好选择,患者耐受性好。
Objective To evaluate the efficacy and safety of linezolid treatment in patients with hematologic malignancies complicated with gram positive cocci infection. Methods Sixteen patients with hematologic malignancies were collected from August 2009 to February 2010, with an average age of (45.6 ± 5.8) years. In the diagnosis of concurrent G + cocci infection or vancomycin treatment was ineffective, linezolid injection was given, while observing the efficacy and adverse reactions before and after treatment. Results After initial empirical therapy was ineffective, patients were treated with linezolid, 15 were cured (93.7%) and 1 was ineffective (6.3%). Bacterial clearance rate of 93.7%. Two cases of clinical adverse reactions (12.5%), mainly varying degrees of alanine aminotransferase (ALT), aspartate aminotransferase (AST) increased, no blood test abnormalities. After liver protection liver function can return to normal. Linezolid is a good choice for the treatment of G + cocci infection in patients with hematologic malignancies, and the patient is well tolerated.